2026-08-23 · wegovy, zepbound, semaglutide, tirzepatide, glp-1, brand comparison, SURMOUNT-5

Are Wegovy and Zepbound the same drug?

No. Both are once-weekly injectable GLP-1 class medications approved for chronic weight management, but the molecules differ. Wegovy is semaglutide 2.4 mg (a GLP-1 receptor agonist made by Novo Nordisk). Zepbound is tirzepatide up to 15 mg (a dual GIP + GLP-1 receptor agonist made by Eli Lilly). They share a mechanism family and a titration pattern, but the drugs, doses, pens, and manufacturers are all different.

Is Zepbound really more effective than Wegovy?

Yes, on average. SURMOUNT-5 (Aronne 2024, NEJM) directly compared the two at maximum tolerated maintenance doses over 72 weeks in adults with obesity and without diabetes. Zepbound produced −20.2% mean total-body weight loss versus −13.7% for Wegovy — a 6.5 percentage-point absolute gap. 65% of Zepbound patients hit ≥15% loss vs 40% on Wegovy; 32% hit ≥25% vs 16%. Individual response still varies.

Which is cheaper in 2026?

For cash-pay patients, Zepbound is materially cheaper because Eli Lilly's LillyDirect self-pay program sells single-dose vials from about $349 to $649 per month depending on dose. Wegovy has no equivalent vial program in 2026, though NovoCare offers a $499 cash-pay pen route for eligible patients. With commercial insurance and a savings card, both effectively cost $25–$100/month after prior authorization.

Can I switch between Wegovy and Zepbound?

Yes, and it is common — usually driven by formulary changes, tolerability, or a plateau. Because the molecules differ, a switch is not dose-for-dose. Prescribers typically restart titration on the new drug at its lowest step to manage GI tolerability, though a shortened titration is sometimes possible after longer exposure. Expect a temporary period of GI adjustment for a few weeks after each dose step up.

Do Wegovy and Zepbound have different side effects?

The side-effect families are the same (nausea, diarrhea, constipation, vomiting, injection-site reactions), but incidence differs slightly. Trial data show Wegovy tends to run modestly higher on nausea (~44% vs ~29%) and vomiting (~24% vs ~13%) at maximum doses. SURMOUNT-5 discontinuation-for-AEs was 6.1% on Zepbound vs 8.0% on Wegovy — a small favor toward Zepbound. Both carry the same boxed warning for medullary thyroid tumors.

Does Medicare cover Wegovy or Zepbound?

Medicare Part D does not cover either drug for weight loss alone — the federal Part D obesity-drug exclusion still applies in 2026. Wegovy is covered under Part D for cardiovascular risk reduction in eligible adults with established CVD (the SELECT indication). Zepbound is covered under Part D for moderate-to-severe obstructive sleep apnea in adults with obesity (the December 2024 SURMOUNT-OSA expansion). Otherwise, expect cash-pay.

Which is easier to inject?

Both are once-weekly single-dose subcutaneous injections delivered by a similar auto-injector pen in the abdomen, thigh, or upper arm. Wegovy uses the Novo Nordisk pen; Zepbound uses the Lilly KwikPen. The needle, injection experience, and once-weekly schedule are functionally identical. Zepbound also has a LillyDirect vial-and-syringe option that requires drawing your own dose, which some patients find less convenient than a pre-loaded pen.

Which should I ask my doctor for?

For most cash-pay patients without insurance, Zepbound via LillyDirect vials is both cheaper and more effective — a straightforward decision. For patients with commercial insurance, step therapy usually forces whichever brand your plan covers first, most often Wegovy. If you have established cardiovascular disease, Wegovy has the SELECT CV-risk indication. If you have moderate-to-severe OSA plus obesity, Zepbound is the only Medicare pathway.

Wegovy vs Zepbound

The one-sentence answer

Wegovy and Zepbound are both FDA-approved GLP-1 class injections for chronic weight management, but Zepbound (tirzepatide, a dual GLP-1/GIP agonist) outperformed Wegovy (semaglutide, GLP-1 alone) head-to-head in SURMOUNT-5 — roughly 20% vs 14% mean total-body weight loss at 72 weeks. For most non-Medicare cash-pay patients in 2026, Zepbound via LillyDirect vials is both cheaper and more effective. For insured patients, plan formularies and prior-authorization rules usually decide, and the practical difference in outcome for most people who tolerate either drug is smaller than the trial gap suggests.

For the same-molecule brand-vs-brand questions, see Mounjaro vs Zepbound and Ozempic vs Wegovy. For the molecule-level comparison, see semaglutide vs tirzepatide.

What each drug is

Wegovy is semaglutide dosed at 2.4 mg subcutaneously once weekly, marketed by Novo Nordisk. It received FDA approval in June 2021 for chronic weight management in adults with obesity (BMI ≥30) or overweight (BMI ≥27) with a weight-related comorbidity. In March 2024, the FDA added a second indication — reducing the risk of major adverse cardiovascular events (MACE) in adults with established cardiovascular disease and either obesity or overweight — on the strength of the SELECT trial (Lincoff 2023, NEJM, n = 17,604; 20% MACE reduction). Semaglutide activates the GLP-1 receptor alone.

Zepbound is tirzepatide dosed 2.5 to 15 mg subcutaneously once weekly, marketed by Eli Lilly. It received FDA approval in November 2023 for chronic weight management on the strength of SURMOUNT-1. In December 2024, the FDA expanded the label to include moderate-to-severe obstructive sleep apnea in adults with obesity, on the strength of SURMOUNT-OSA (Malhotra 2024, NEJM) — the first medication ever specifically approved for OSA in an obesity context. Tirzepatide activates two gut-hormone receptors — GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) — which is thought to explain the larger appetite-suppressive and weight-loss effect seen in trials (Coskun 2018, Molecular Metabolism; Frías 2018, SURPASS-1).

Head-to-head efficacy — SURMOUNT-5 (the definitive comparison)

SURMOUNT-5 (Aronne 2024, NEJM, n = 751, 72 weeks) is the only large randomized trial that directly compared the two drugs at their maximum tolerated maintenance doses in adults with obesity and without type 2 diabetes. Both arms received identical intensive lifestyle counseling. The results are the single strongest piece of comparative evidence on this pair.

• Mean total-body weight loss: −20.2% on tirzepatide vs −13.7% on semaglutide.
• Absolute treatment difference: −6.5 percentage points (95% CI −8.1 to −4.9).
• ≥15% weight loss response: 65% on tirzepatide vs 40% on semaglutide.
• ≥25% weight loss response: 32% on tirzepatide vs 16% on semaglutide.

The trial dosed to maximum tolerated on each arm, which means the numbers reflect what a highly adherent patient on the ceiling dose can expect, not an average-adherence real-world clinic. This is the one comparison that matters when you are weighing “how much more will Zepbound deliver on average than Wegovy” — every other number is a cross-trial inference. Individual response still varies substantially, and a significant minority of patients on Wegovy hit ≥15% loss while a significant minority on Zepbound do not.

Registrational-trial efficacy — for context

For readers who want the individual-drug numbers behind each brand’s label:

• STEP-1 (Wilding 2021, NEJM, n = 1,961; 68 weeks): semaglutide 2.4 mg produced −14.9% mean weight loss versus −2.4% on placebo in adults with obesity without diabetes.
• SURMOUNT-1 (Jastreboff 2022, NEJM, n = 2,539; 72 weeks): tirzepatide 15 mg produced −20.9% mean weight loss versus −3.1% on placebo, with 10 mg at ~−19.5% and 5 mg at ~−15% in the same trial.

The −20.9% vs −14.9% cross-trial gap looks similar to the SURMOUNT-5 head-to-head result, but the two trials enrolled slightly different populations, used different endpoints, and delivered different intensities of lifestyle counseling. Comparing across trials always overstates or understates the true molecule-level difference by a few percentage points in one direction or the other; SURMOUNT-5 is why the head-to-head number matters. For a fuller walk through the STEP and SURMOUNT programs, see GLP-1 medications compared.

Side-effect comparison table

Common gastrointestinal side effects at maximum doses, drawn primarily from STEP-1 (Wegovy) and SURMOUNT-1 (Zepbound) with SURMOUNT-5 confirmatory data:

SURMOUNT-5 discontinuation-for-AEs was 6.1% on Zepbound vs 8.0% on Wegovy — a modest tolerability edge to Zepbound, but small enough that individual response dominates. Both drugs share the same class-level serious risks: the boxed warning for thyroid C-cell tumors (rodent data; contraindicated in personal or family history of medullary thyroid carcinoma or MEN2), uncommon pancreatitis, gallbladder disease (particularly with rapid loss), and dehydration-related acute kidney injury from persistent vomiting or diarrhea. For a deeper look at the class-wide GI titration profile, see Ozempic side effects — the same practical guidance (small protein-forward meals, steady hydration, holding a step an extra four weeks when a level is not tolerated) applies to both drugs.

Cost comparison in 2026

Cash prices differ; insurance-adjusted costs largely do not. All figures are typical 2026-Q2 US retail — confirm current numbers with the manufacturer or your pharmacy.

For cash-pay in 2026, Zepbound via LillyDirect vials is materially cheaper across the dose range; with commercial insurance, both effectively cost the same after prior authorization; and Medicare Part D excludes both for a weight-only indication. For a fuller multi-brand cost walkthrough — telehealth bundles, savings-card mechanics, UK NHS and private-clinic pricing — see GLP-1 cost and insurance coverage.

Insurance and prior authorization

Commercial-plan gatekeeping is nearly identical for both drugs. Plans that cover either brand typically require:

• documented BMI ≥30, or ≥27 with a weight-related comorbidity (hypertension, dyslipidemia, sleep apnea, prediabetes);
• prior authorization on every fill and often at annual re-authorization;
• documented history of prior lifestyle-intervention attempts.

Where the two brands diverge is on Medicare Part D, because the federal obesity-drug exclusion in the Social Security Act still stands in 2026 and neither is covered for a weight-only indication. Each brand has one lever that opens a narrow Part D pathway under a different indication:

• Wegovy → cardiovascular risk reduction. The March 2024 SELECT indication opened Part D coverage for adults with established CVD (prior MI, stroke, or symptomatic peripheral artery disease) plus obesity or overweight. This is the largest Wegovy-only coverage lever.
• Zepbound → moderate-to-severe OSA. The December 2024 SURMOUNT-OSA indication opened Part D coverage for adults with obesity and moderate-to-severe OSA meeting AHI criteria. This is the largest Zepbound-only coverage lever.

For patients with neither CVD nor OSA, Medicare Part D covers neither brand for weight loss alone.

Dose escalation and injection experience

Both are once-weekly subcutaneous injections delivered by single-dose auto-injector pens in the abdomen, thigh, or upper arm. The needle, injection experience, and once-a-week schedule are functionally identical. The pens differ in brand — Wegovy uses Novo Nordisk’s pen; Zepbound uses Lilly’s KwikPen — but not in daily-use experience.

Titration schedules differ modestly:

• Wegovy: 0.25 mg → 0.5 mg → 1.0 mg → 1.7 mg → 2.4 mg, one step every 4 weeks. Full titration typically 16–20 weeks.
• Zepbound: 2.5 mg → 5 mg → 7.5 mg → 10 mg → 12.5 mg → 15 mg, one step every 4 weeks. Full titration typically 20–24 weeks.

Zepbound has more titration steps but also more dose granularity for tolerability holds — a patient who does not tolerate 10 mg can drop to 7.5 mg without stepping all the way back to 5 mg. Wegovy has one fewer step but no equivalent mid-range dose between 1.7 and 2.4 mg. The LillyDirect Zepbound vial-and-syringe option requires the patient to draw the dose from a vial rather than click a pre-loaded pen, which is a real day-of-injection usability difference some patients find inconvenient.

Which one for which patient — decision matrix

Honest framing: for most non-Medicare cash-pay patients in 2026, Zepbound is both cheaper and more effective — the decision is uncomplicated. For most insured patients, the plan formulary makes the choice for you, and the practical difference in outcome for someone who tolerates either drug is smaller than the trial gap. The most useful conversation with your prescriber is usually “which of these does my plan cover first, and what does prior authorization require,” not “which is technically better on average.”

What both do NOT do

• Not a substitute for a calorie deficit. Both drugs work by reducing appetite, but the trial-level 15–20% loss numbers came from patients receiving intensive lifestyle counseling in addition to the drug. Real-world outcomes without that infrastructure land several percentage points lower.
• Not FDA-approved for type 2 diabetes. Ozempic and Mounjaro are the T2D-labeled siblings of Wegovy and Zepbound respectively. If you have T2D, the covered pathway is almost always the T2D-indication brand.
• Not legally available as compounded formulations. The Wegovy shortage was resolved in October 2024 and the tirzepatide shortage in December 2024. The FDA-shortage compounding carve-outs that once permitted 503A compounded versions of both molecules no longer apply. Any 2026 product marketed as compounded semaglutide or tirzepatide is operating outside current FDA enforcement priorities — see compounded semaglutide and tirzepatide safety.
• Not head-to-head tested against retatrutide, mazdutide, or pipeline drugs. SURMOUNT-5 is the definitive Wegovy-vs-Zepbound comparison; there is no analogous head-to-head data yet for either brand against the next generation of triple agonists — see retatrutide vs tirzepatide and next generation weight loss drugs for what is in trials.
• Not a short course. Both are chronic therapies. STEP-4 (semaglutide withdrawal) and SURMOUNT-4 (tirzepatide withdrawal) both show 50–70% of lost weight returning within 12 months of stopping — see rebound weight gain after stopping GLP-1.

Practical 2026 bottom line

If you are cash-pay, choose Zepbound and use the LillyDirect vial program. If you are insured with prior authorization, take whichever your plan covers on first submission — usually Wegovy — because the switching cost is real and the outcome for a tolerant patient is close enough. If you have Medicare with OSA, Zepbound is your only pathway; if you have Medicare with established CVD, Wegovy is your only pathway. If a formulary change or a cost move forces you to move between the two drugs, the mechanics — no washout, restart at the lowest step of the new drug, expect 4 to 6 weeks of GI adjustment — are covered in how to switch between GLP-1 medications. See GLP-1 cost and insurance coverage for the full payer walkthrough, and Wegovy for weight loss or Zepbound for weight loss for each drug’s standalone deep dive.

Frequently asked questions

Are Wegovy and Zepbound the same drug? No. Both are once-weekly injectable GLP-1 class medications approved for chronic weight management, but the molecules differ. Wegovy is semaglutide 2.4 mg (a GLP-1 receptor agonist made by Novo Nordisk). Zepbound is tirzepatide up to 15 mg (a dual GIP + GLP-1 receptor agonist made by Eli Lilly). They share a mechanism family and a titration pattern, but the drugs, doses, pens, and manufacturers are all different.

Is Zepbound really more effective than Wegovy? Yes, on average. SURMOUNT-5 (Aronne 2024, NEJM) directly compared the two at maximum tolerated maintenance doses over 72 weeks in adults with obesity and without diabetes. Zepbound produced −20.2% mean total-body weight loss versus −13.7% for Wegovy — a 6.5 percentage-point absolute gap. 65% of Zepbound patients hit ≥15% loss vs 40% on Wegovy; 32% hit ≥25% vs 16%. Individual response still varies.

Which is cheaper in 2026? For cash-pay patients, Zepbound is materially cheaper because Eli Lilly’s LillyDirect self-pay program sells single-dose vials from about $349 to $649 per month depending on dose. Wegovy has no equivalent vial program in 2026, though NovoCare offers a $499 cash-pay pen route for eligible patients. With commercial insurance and a savings card, both effectively cost $25–$100/month after prior authorization.

Can I switch between Wegovy and Zepbound? Yes, and it is common — usually driven by formulary changes, tolerability, or a plateau. Because the molecules differ, a switch is not dose-for-dose. Prescribers typically restart titration on the new drug at its lowest step to manage GI tolerability, though a shortened titration is sometimes possible after longer exposure. Expect a temporary period of GI adjustment for a few weeks after each dose step up.

Do Wegovy and Zepbound have different side effects? The side-effect families are the same (nausea, diarrhea, constipation, vomiting, injection-site reactions), but incidence differs slightly. Trial data show Wegovy tends to run modestly higher on nausea (~44% vs ~29%) and vomiting (~24% vs ~13%) at maximum doses. SURMOUNT-5 discontinuation-for-AEs was 6.1% on Zepbound vs 8.0% on Wegovy — a small favor toward Zepbound. Both carry the same boxed warning for medullary thyroid tumors.

Does Medicare cover Wegovy or Zepbound? Medicare Part D does not cover either drug for weight loss alone — the federal Part D obesity-drug exclusion still applies in 2026. Wegovy is covered under Part D for cardiovascular risk reduction in eligible adults with established CVD (the SELECT indication). Zepbound is covered under Part D for moderate-to-severe obstructive sleep apnea in adults with obesity (the December 2024 SURMOUNT-OSA expansion). Otherwise, expect cash-pay.

Which is easier to inject? Both are once-weekly single-dose subcutaneous injections delivered by a similar auto-injector pen in the abdomen, thigh, or upper arm. Wegovy uses the Novo Nordisk pen; Zepbound uses the Lilly KwikPen. The needle, injection experience, and once-weekly schedule are functionally identical. Zepbound also has a LillyDirect vial-and-syringe option that requires drawing your own dose, which some patients find less convenient than a pre-loaded pen.

Which should I ask my doctor for? For most cash-pay patients without insurance, Zepbound via LillyDirect vials is both cheaper and more effective — a straightforward decision. For patients with commercial insurance, step therapy usually forces whichever brand your plan covers first, most often Wegovy. If you have established cardiovascular disease, Wegovy has the SELECT CV-risk indication. If you have moderate-to-severe OSA plus obesity, Zepbound is the only Medicare pathway.

How this article was researched

This article draws on the SURMOUNT-5 head-to-head trial (Aronne 2024, NEJM), the STEP-1 pivotal trial for semaglutide (Wilding 2021, NEJM), the SURMOUNT-1 pivotal trial for tirzepatide (Jastreboff 2022, NEJM), the SELECT cardiovascular-outcomes trial (Lincoff 2023, NEJM), the SURMOUNT-OSA trial (Malhotra 2024, NEJM), FDA prescribing information for Wegovy and Zepbound, the FDA Drug Shortage database for the 2024 resolution of the tirzepatide and semaglutide shortages, and publicly available Novo Nordisk and Eli Lilly cash-pay pricing. Coverage and pricing details reflect 2026-Q2 US commercial and Medicare Part D norms and will move; confirm specific numbers with your insurer, clinician, or manufacturer before making a decision.